PathWhiz

PathWhiz ID	Pathway	Meta Data
PW122274 View Pathway	drug action Piroxicam Action Action Pathway Xuan (Demo Purpose) Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: xuan cao Created On: October 29, 2018 at 14:59 Last Updated: October 29, 2018 at 14:59
PW122326 View Pathway	drug action Piroxicam Action Action Pathway Xuan (Demo Purpose) 2 Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Carin Li Created On: January 17, 2019 at 14:24 Last Updated: January 17, 2019 at 14:24
PW000125 View Pathway	drug action Piroxicam Action Pathway Homo sapiens Piroxicam (also named Feldene or Piroxicamum) is a nonsteroidal anti-inflammatory drug. Piroxicam can block prostaglandin synthesis by the action of inhibition of prostaglandin G/H synthase 1 and 2. Prostaglandin G/H synthase 1 and 2 catalyze the arachidonic acid to prostaglandin G2, and also catalyze prostaglandin G2 to prostaglandin H2 in the metabolism pathway. Decreased prostaglandin synthesis in many animal model's cell is caused by presence of piroxicam. Piroxicam can prevent movement of leukocytes to inflammation site so that thromboxane A2 can't be produced. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: WishartLab Created On: August 04, 2013 at 12:28 Last Updated: August 04, 2013 at 12:28
PW144671 View Pathway	drug action Piroxicam Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 14:10 Last Updated: October 07, 2023 at 14:10
PW126071 View Pathway	drug action Piroxicam NSAID Action Pathway Homo sapiens Piroxicam is an NSAID used to treat the symptoms of osteoarthritis and rheumatoid arthritis. It targets the prostaglandin G/H synthase-1 (COX-1) and prostaglandin G/H synthase-2 (COX-2) in the cyclooxygenase pathway. The cyclooxygenase pathway begins in the cytosol with phospholipids being converted into arachidonic acid by the action of phospholipase A2. The rest of the pathway occurs on the endoplasmic reticulum membrane, where prostaglandin G/H synthase 1 & 2 converts arachidonic acid into prostaglandin H2. Prostaglandin H2 can either be converted into thromboxane A2 via thromboxane A synthase, prostacyclin/prostaglandin I2 via prostacyclin synthase or prostaglandin E2 via prostaglandin E synthase. COX-2 is an inducible enzyme, and during inflammation, it is responsible for prostaglandin synthesis. It leads to the formation of prostaglandin E2 which is responsible for contributing to the inflammatory response by activating immune cells and for increasing pain sensation by acting on pain fibers. The anti-inflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Karxena Harford Created On: June 09, 2021 at 00:23 Last Updated: June 09, 2021 at 00:23
PW132545 View Pathway	metabolic Pirtobrutinib Drug Metabolism Homo sapiens Pirtobrutinib is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Pirtobrutinib passes through the liver and is then excreted from the body mainly through the kidney. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: September 21, 2023 at 22:21 Last Updated: September 21, 2023 at 22:21
PW128268 View Pathway	drug action Pitavastatin Action Pathway Homo sapiens Pitavastatin, also known as Livalo, is an hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor. This drug is a lipid-lowering drug belonging to the statin class of medications. The inhibited enzyme is catalyzing the conversion of HMG-CoA to mevalonic acid, the third step of the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL). This drug is indicated for the treatment of hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C). Statin medication prescriptions can be given following any cardiovascular events and to people with a moderate risk of development of CVD. Pitavastatin mainly operates within the liver, where it prompts the liver to increase the production of low-density lipoprotein (LDL) receptors due to lowered cholesterol levels. This rise in the production of receptors enhances the liver's ability to absorb LDL, leading to a reduction in circulating LDL-C levels. This drug is administered as an oral tablet. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Daphnee Created On: August 11, 2023 at 16:04 Last Updated: August 11, 2023 at 16:04
PW145853 View Pathway	drug action Pitavastatin Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 16:49 Last Updated: October 07, 2023 at 16:49
PW146418 View Pathway	drug action Pitolisant Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 18:09 Last Updated: October 07, 2023 at 18:09
PW176951 View Pathway	drug action Pivampicillin Action Pathway Escherichia coli Pivampicillin is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics.5 It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections. Pivampicillin exhibits a bactericidal mode of action. It works by binding to and inhibiting bacterial penicillin-binding proteins (PBPs).5 In Escherichia coli, it has a strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preferential binding to PBPs 2 and 3.5 Upon binding to PBPs, ertapenem inhibits bacterial cell wall synthesis by interfering with the lengthening and strengthening of the peptidoglycan portion of the cell wall, thereby inhibiting cell wall synthesis. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Karxena Harford Created On: January 02, 2024 at 09:19 Last Updated: January 02, 2024 at 09:19